北京福元医药股份有限公司2025年半年度报告摘要

Core Points - The company has released its 2025 semi-annual report, which includes financial results and future development plans [1][3] - The board of directors and supervisory board have confirmed the authenticity and completeness of the report [2][7] - The report has not been audited [1] Company Overview - Beijing Fuyuan Pharmaceutical Co., Ltd. is the company in focus, with its stock code being 601089 [1] - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [1] Important Matters - The company has not reported any significant changes in its operational situation during the reporting period [1] - The board of directors approved the semi-annual report and its summary, which reflects the company's financial status and operational results [3][4] Fundraising and Usage - The company raised a total of RMB 1,754.4 million from its initial public offering, with a net amount of RMB 1,635.92 million after deducting issuance costs [16][17] - As of June 30, 2025, the company had two fundraising accounts with a total balance of RMB 124.35 million [18][19] - The company has not used idle fundraising for temporary working capital or other purposes during the reporting period [20][22] Fund Management - The company has established a fundraising management system to ensure the proper use and supervision of the funds [18] - A tripartite supervision agreement was signed with the underwriter and banks to regulate the management of the fundraising [18] Changes in Fundraising Projects - The company has made adjustments to some fundraising project implementations based on its actual situation and development strategy [24] - There have been no transfers or replacements of fundraising investment projects during the reporting period [25] Issues in Fund Usage and Disclosure - The company has disclosed information regarding the use of fundraising in a timely and accurate manner, with no violations reported [26]